reports
- Research Department
INFORME DIARIO 13 FEBRERO + RDOS. ESPAÑA. IDEAS DESTACADAS Y PREVIEWS ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: REPSOL, TELEFÓNICA. EUROPA: HERMÈS INT., L’ORÉAL, SAFRAN. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Siguen las dudas sobre la rentabilidad de la IA Las bolsas europeas revertieron las ganancias en el tramo final de la sesión, presionadas...
- Research Department
IBERIAN DAILY 13 FEBRUARY + 4Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: REPSOL, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Doubts on AI profitability continue European stock markets reversed the gains at the end of the session, pressured by the uncertainty surrounding margins in the US tech sector (the Nasdaq fell -2.0%) and by sales in commodities and crypto...
- Research Department
INFORME DIARIO 12 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: EUROPA: AB INBEV, AHOLD DELHAIZE, ASML, DEUTSCHE TELEKOM, ESSILORLUXOTTICA, MERCEDES BENZ GROUP, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El dato de empleo en EE.UU. agita los mercados Jornada de más a menos en las bolsas europeas, que ...
Press Release: Belén Garijo to become Chief Executive Officer of Sanof...
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson’s last day as Chief Executive Officer will be on February 17, 2026 at the end of business. The Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years. Following the proposal of the Appointments Committee, the Board of Directors app...
Communiqué de presse : Belén Garijo nommée Directrice générale de Sano...
Communiqué de presse : Belén Garijo nommée Directrice générale de Sanofi Belén Garijo nommée Directrice générale de Sanofi Paris, le 12 février 2026. Le Conseil d’administration de Sanofi s’est réuni le 11 février 2026 et a décidé de ne pas renouveler le mandat d’administrateur de Paul Hudson. Par conséquent, Paul Hudson quittera ses fonctions de Directeur général le 17 février 2026 au soir. Le Conseil le remercie pour sa contribution significative à la transformation et au développement du Groupe au cours des six dernières années. Sur proposition du Comité des nominations, le Conseil d’a...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares – January 2026 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,438,854,192Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – JANVIER 2026 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 438 854 192 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actio...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Coffee, Croissants & Credit/Alphabet, Telefonica, Gecina, WP Carey
Alphabet goes with CHF and GBP – but Reverse Yankee supply is still set to rise / Telefonica has agreed to sell Telefonica Chile / Gecina FY25: solid results, notes momentum continues to build in Paris prime offices / WP Carey 4Q25: beats consensus and increases 2026 guidance
- Chris Hoare
Millicom (Buy, TP: $70, +7%) Millicom acquires Telefonica Chile: A po...
Millicom has announced today that it has acquired a 49% stake in Telefonica Chile, with the option to buy the remaining 51% in year 5 and 6 post closing. We see this deal as a potentially valuable option, though market may have concerns Millicom is stretching management too thinly.
- Research Department
IBERIAN DAILY 11 FEBRUARY + 4Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: ENDESA, INDRA, INSURANCE SECTOR, SANTANDER, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Ibex remains at 18,100 points Stock markets fell in a transition session, waiting the employment data to be released today in the US. In the STOXX 600, the best-performing sectors were Chemicals and Aut...
- Research Department
INFORME DIARIO 11 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENDESA, INDRA, SANTANDER, SECTOR SEGUROS, TELEFÓNICA. EUROPA: AHOLD DELHAIZE, BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex mantiene los 18.100 puntos Ligeras caídas en los mercados en una jornada de transición a la espera de l...
- Chris Hoare
- David Lopes
Press Release: Sanofi completes the acquisition of Dynavax
Press Release: Sanofi completes the acquisition of Dynavax Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. This acquisition augments Sanofi’s presence in adult immunization by bringing togethe...
Communiqué de presse : Sanofi finalise l’acquisition de Dynavax
Communiqué de presse : Sanofi finalise l’acquisition de Dynavax Sanofi finalise l’acquisition de Dynavax Paris, le 10 février 2026. Sanofi a annoncé aujourd’hui avoir finalisé l’ (Dynavax). L’acquisition comprend le vaccin contre l’hépatite B pour adultes de Dynavax, HEPLISAV-B, actuellement commercialisé aux États-Unis et qui se distingue par son schéma vaccinal à deux doses administrées sur un mois. Elle comprend également le vaccin candidat contre le zona de Dynavax (Z-1018), actuellement en phase 1/2 d’essais cliniques, ainsi que d’autres projets de vaccins en développement. Cette ac...
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy ...
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for warm autoimmune hemolytic anemia to be designated Breakthrough Therapy by the FDA Rilzabrutinib helps address complex immune-system dysregulation through multi-immune modulationRilzabrutinib holds global regulatory designations acr...
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme t...
Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le rilzabrutinib est le premier et le seul BTKi expérimental pour l’’anémie hémolytique auto-immune à anticorps chauds à être désigné comme thérapie innovante par la FDA. Le rilzabrutinib...
- Carole Braudeau
- Carole Braudeau
- Research Department
INFORME DIARIO 06 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T'25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENCE, INDRA, RDOS. ESPAÑA, TELEFONICA. EUROPA: RDOS. EUROPA, SOCIETE GENERAL, VINCI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Las dudas no desaparecen Jornada de números rojos en las bolsas europeas, arrastradas por las caídas en Estados...
- Research Department
IBERIAN DAILY 06 FEBRUARY + 4Q’25 RESULTS. HIGHLIGHTS (ANÁLISIS BANCO ...
NEWS SUMMARY: ENCE, INDRA, RESULTS HIGHLIGHTS, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Doubts remain present It was a session of drops for European stock markets, dragged down by corrections in the US and Asia and where the sell-off in software and data services companies continues. In the STOXX 600...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.